The Chemours Company (NYSE:CC) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,491,748 shares of the specialty chemicals company's stock after buying an additional 28,803 shares during the period. Geode Capital Management LLC owned about 1.67% of Chemours worth $50,646,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CC. Matrix Trust Co bought a new stake in Chemours during the 3rd quarter worth approximately $25,000. Blue Trust Inc. lifted its stake in shares of Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 731 shares in the last quarter. Truvestments Capital LLC bought a new position in Chemours in the 3rd quarter worth $35,000. Brooklyn Investment Group bought a new stake in Chemours during the third quarter valued at about $37,000. Finally, Signaturefd LLC grew its position in shares of Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after purchasing an additional 1,216 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares of the company's stock, valued at $343,552.80. This represents a 31.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.47% of the company's stock.

Chemours Trading Down 2.0 %

CC traded down $0.36 on Monday, reaching $17.36. 237,992 shares of the company traded hands, compared to its average volume of 1,597,990. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The company has a market cap of $2.59 billion, a P/E ratio of 34.72 and a beta of 1.80. The firm has a fifty day simple moving average of $19.72 and a two-hundred day simple moving average of $20.54. The Chemours Company has a one year low of $15.10 and a one year high of $32.70.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the previous year, the business posted $0.64 EPS. The company's quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts expect that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, November 15th. This represents a $1.00 annualized dividend and a dividend yield of 5.76%. Chemours's payout ratio is currently 200.00%.

Analyst Ratings Changes

CC has been the topic of a number of research reports. The Goldman Sachs Group reduced their price target on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating on the stock in a report on Tuesday, September 3rd. Morgan Stanley lowered their price objective on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th. Barclays increased their price target on shares of Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Royal Bank of Canada restated an "outperform" rating and set a $25.00 price objective on shares of Chemours in a research report on Thursday, December 12th. Finally, BMO Capital Markets lifted their target price on Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $24.88.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.